Skip to content

US · SNDX · BIOTECHNOLOGY

Syndax Pharmaceuticals, Inc. (SNDX) intrinsic value and stock valuation

$8.72as of 2026-11-21 · Mkt cap 1.81B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Syndax Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values SNDX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from SNDX’s statements →

Syndax Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New York City, NY 10017 syndax.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$172.4M+157.6% 5y CAGRd
20112025
Net income
-$-285.42M
20112025
Free cash flow
-$-323.17M
20112025
Total equity
$64.6M-23.8% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$172.4M$23.7M$0.00$0.00$139.7M
Operating income-$-273.08M-$-339.67M-$-229.95M-$-151.76M$26.2M
Net income-$-285.42M-$-318.76M-$-209.36M-$-149.34M$24.9M
EPSd-$-3.29M-$-3.72M-$-2.98M-$-2.46M$478.9K
Operating cash flow-$-322.98M-$-274.9M-$-160.6M-$-133.68M$29.1M
Capital expenditure-$-190K$0.00$0.00-$-230K-$-130K
Free cash flow-$-323.17M-$-274.9M-$-160.6M-$-133.9M$29M
Total assets$529.7M$724.8M$612.9M$497.2M$449.7M
Total debt$346.5M$345.7M$1.64M$1.16M$21M
Net debt$211.6M$191.7M-$-293.76M-$-73.19M-$-201M
Total equity$64.6M$288.1M$554.2M$467.5M$408.4M
Cash and short-term investments$413.7M$582.9M$577.6M$484.4M$446.8M
Income statement
20252024202320222021
Revenue$172.4M$23.7M$0.00$0.00$139.7M
Cost of revenue$6.97M$830K$0.00$0.00$0.00
Gross profit$165.4M$22.9M$0.00$0.00$139.7M
Research and development expenses$258.8M$241.7M$163M$118.5M$88.3M
Selling, general and administrative expenses$179.7M$120.9M$66.9M$33.3M$25.2M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$438.5M$362.5M$230M$151.8M$113.5M
Cost and expenses$445.4M$363.4M$230M$151.8M$113.5M
Interest income$22.7M$26.1M$21.2M$5.87M$400K
Interest expense$33.8M$4.93M$210K$3.14M$1.9M
Depreciation and amortization$10K$10K$10K$30K$40K
Ebitda-$-251.63M-$-313.82M-$-209.14M-$-146.17M$26.9M
Operating income-$-273.08M-$-339.67M-$-229.95M-$-151.76M$26.2M
Total other income/expenses, net-$-12.34M$20.9M$20.6M$2.42M-$-1.29M
Income before tax-$-285.42M-$-318.76M-$-209.36M-$-149.34M$24.9M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-285.42M-$-318.76M-$-209.36M-$-149.34M$24.9M
Weighted average shares outstanding$86.6M$85.6M$70.4M$60.8M$52.1M
Weighted average diluted shares outstanding$86.6M$85.6M$70.4M$60.8M$52.1M
Balance sheet
20252024202320222021
Cash and short-term investments$413.7M$582.9M$577.6M$484.4M$446.8M
Net receivables$70.3M$13.9M$1.23M$4.06M$430K
Inventory$32.8M$370K$0.00$0.00$0.00
Total current assets$528.1M$603.1M$580.9M$489.8M$448.4M
Property, plant and equipment, net$1.52M$2.02M$1.5M$1.06M$1.26M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$119.5M$29.8M$5.47M$0.00
Total non-current assets$1.62M$121.8M$32M$7.45M$1.26M
Total assets$529.7M$724.8M$612.9M$497.2M$449.7M
Accounts payable$16.6M$11.6M$9.96M$4.35M$5.67M
Short-term debt$470K$12.6M$1.05M$440K$360K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$120.1M$103.6M$58.1M$29.1M$20.7M
Long-term debt$346M$333.1M$590K$720K$20.6M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$345M$333.1M$590K$720K$20.6M
Capital lease obligations$1.52M$2.06M$1.64M$1.16M$1.07M
Total liabilities$465.1M$436.7M$58.7M$29.8M$41.3M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-1.51B-$-1.22B-$-902.4M-$-693.04M-$-543.7M
Accumulated other comprehensive income (loss)$450K$160K$220K-$-810K$40K
Total equity$64.6M$288.1M$554.2M$467.5M$408.4M
Total investments$278.8M$548.4M$312M$415.5M$224.9M
Total debt$346.5M$345.7M$1.64M$1.16M$21M
Net debt$211.6M$191.7M-$-293.76M-$-73.19M-$-201M
Cash flow statement
20252024202320222021
Net income-$-285.42M-$-318.76M-$-209.36M-$-149.34M$24.9M
Depreciation and amortization$10K$10K$10K$30K$40K
Stock-based compensation$47.5M$43M$31M$16M$13.3M
Change in working capital-$-79.32M$13.3M$31.9M$1.66M-$-9.6M
Accounts receivable-$-36.83M-$-11.24M$10.7M-$-3.47M$0.00
Inventory-$-32.09M-$-370K$0.00$3.47M$0.00
Accounts payable$4.95M$1.67M$5.61M-$-1.32M$2.16M
Net cash provided by operating activities-$-322.98M-$-274.9M-$-160.6M-$-133.68M$29.1M
Investments in property, plant and equipment-$-190K$0.00$0.00-$-230K-$-130K
Acquisitions, net$0.00$0.00$0.00$230K$40K
Net cash used for investing activities$290M-$-219.78M$117.6M-$-186.19M-$-40.87M
Common stock issued$13.7M$9.71M$258.1M$181.4M$86.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$13.7M$353.4M$264.1M$172.3M$118.5M
Net change in cash-$-19.27M-$-141.31M$221.1M-$-147.61M$106.7M
Cash at end of period$135M$154.3M$295.6M$74.5M$222.1M
Operating cash flow-$-322.98M-$-274.9M-$-160.6M-$-133.68M$29.1M
Capital expenditure-$-190K$0.00$0.00-$-230K-$-130K
Free cash flow-$-323.17M-$-274.9M-$-160.6M-$-133.9M$29M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Syndax Pharmaceuticals, Inc.

        Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.

        CEO
        Michael A. Metzger
        Employees
        298
        Beta
        0.37

        Explore

        Frequently asked questions

        What is the intrinsic value of Syndax Pharmaceuticals, Inc. (SNDX)?

        Syndax Pharmaceuticals, Inc. (SNDX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is SNDX undervalued?

        SNDX trades at a price of $8.72 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.